Cargando…
Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement of other organ systems. It is generally believed that the autoimmune response (auto...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681571/ https://www.ncbi.nlm.nih.gov/pubmed/23758833 http://dx.doi.org/10.1186/2044-5040-3-13 |
_version_ | 1782273275357822976 |
---|---|
author | Rayavarapu, Sree Coley, William Kinder, Travis B Nagaraju, Kanneboyina |
author_facet | Rayavarapu, Sree Coley, William Kinder, Travis B Nagaraju, Kanneboyina |
author_sort | Rayavarapu, Sree |
collection | PubMed |
description | Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement of other organ systems. It is generally believed that the autoimmune response (autoreactive lymphocytes and autoantibodies) to skeletal muscle-derived antigens is responsible for the muscle fiber damage and muscle weakness in this group of disorders. Therefore, most of the current therapeutic strategies are directed at either suppressing or modifying immune cell activity. Recent studies have indicated that the underlying mechanisms that mediate muscle damage and dysfunction are multiple and complex. Emerging evidence indicates that not only autoimmune responses but also innate immune and non-immune metabolic pathways contribute to disease pathogenesis. However, the relative contributions of each of these mechanisms to disease pathogenesis are currently unknown. Here we discuss some of these complex pathways, their inter-relationships and their relation to muscle damage in myositis. Understanding the relative contributions of each of these pathways to disease pathogenesis would help us to identify suitable drug targets to alleviate muscle damage and also improve muscle weakness and quality of life for patients suffering from these debilitating muscle diseases. |
format | Online Article Text |
id | pubmed-3681571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36815712013-06-14 Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness Rayavarapu, Sree Coley, William Kinder, Travis B Nagaraju, Kanneboyina Skelet Muscle Review Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement of other organ systems. It is generally believed that the autoimmune response (autoreactive lymphocytes and autoantibodies) to skeletal muscle-derived antigens is responsible for the muscle fiber damage and muscle weakness in this group of disorders. Therefore, most of the current therapeutic strategies are directed at either suppressing or modifying immune cell activity. Recent studies have indicated that the underlying mechanisms that mediate muscle damage and dysfunction are multiple and complex. Emerging evidence indicates that not only autoimmune responses but also innate immune and non-immune metabolic pathways contribute to disease pathogenesis. However, the relative contributions of each of these mechanisms to disease pathogenesis are currently unknown. Here we discuss some of these complex pathways, their inter-relationships and their relation to muscle damage in myositis. Understanding the relative contributions of each of these pathways to disease pathogenesis would help us to identify suitable drug targets to alleviate muscle damage and also improve muscle weakness and quality of life for patients suffering from these debilitating muscle diseases. BioMed Central 2013-06-07 /pmc/articles/PMC3681571/ /pubmed/23758833 http://dx.doi.org/10.1186/2044-5040-3-13 Text en Copyright © 2013 Rayavarapu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Rayavarapu, Sree Coley, William Kinder, Travis B Nagaraju, Kanneboyina Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
title | Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
title_full | Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
title_fullStr | Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
title_full_unstemmed | Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
title_short | Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
title_sort | idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681571/ https://www.ncbi.nlm.nih.gov/pubmed/23758833 http://dx.doi.org/10.1186/2044-5040-3-13 |
work_keys_str_mv | AT rayavarapusree idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness AT coleywilliam idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness AT kindertravisb idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness AT nagarajukanneboyina idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness |